“Diabesity” represents a growing global health concern, demonstrating the strong biological link between obesity and type 2 diabetes. This highlights the need for treatment strategies that address both weight and diabetes together. Since several antidiabetic agents can cause weight gain, choosing therapies that minimise this risk is essential. 1 Semaglutide has shown meaningful reductions in body weight, HbA1c, and insulin requirements, with a favorable safety profile.
2 Join us for an impactful clinical webinar on 10th January 2026 at 7:00 PM IST , where leading experts will address the rising burden of diabesity in everyday practice. The sessions will explore evolving real-world strategies for comprehensive metabolic management, including why semaglutide 1.0 mg is increasingly being adopted as a first-line option in eligible patients. ##References## Rehman Tet al. Indian Journal of…
